大环内酯类抗生素联合舒利迭治疗哮喘COPD重叠综合征的疗效分析

Efficacy Analysis of Macrolide Antibiotics Combined with Seretide in the Treatment of Asthma COPD Overlap Syndrome

目的:探讨大环内酯类抗生素联合吸入沙美特罗替卡松粉吸入剂治疗哮喘COPD重叠综合征的临床疗效。方法:选取笔者所在医院2012年10月-2013年10月收治的60例ACOS患者作为研究对象,按照随机双盲原则将其分为治疗组和对照组,每组30例。两组患者均给予基础治疗,对照组在此基础上给予舒利迭治疗,治疗组给予红霉素联合舒利迭治疗。观察比较两组患者治疗前后的肺功能测定结果及随访期间内急性发作频率及急性发作间隔时间。结果:经治疗1年后,两组的FEV1、FEV1/FVC、FEV1%预计值均明显高于治疗前,且治疗组上述指标均明显高于对照组,差异均有统计学意义(P<0.05),在随访期间内,治疗组的急性发作频率明显低于对照组,急性发作间隔时间明显长于对照组,差异均有统计学意义(P<0.05)。结论:大环内酯类抗生素联合吸入沙美特罗替卡松粉吸入剂治疗ACOS患者疗效显著,可以改善患者临床症状及肺功能情况,减少发作频率,延长急性发作间隔时间,值得临床推广使用。

Objective：To investigate the clinical efficacy of Macrolide Antibiotics combined with Salmeterol Assigned Powder Inhaler in the treatment of asthma COPD overlap syndrome.Method：60 patients with ACOS admitted to our hospital from October 2012 to October 2013 were selected as research objects,they were divided into the treatment group and the control group according to the randomized double blind principle,30 cases in each group.The two groups were given basic treatment.On the basic treatment,the control group was only given Seretide,the treatment group was given Erythromycin combined with Seretide.The determination results of pulmonary function between the two groups before and after treatment,the acute onset frequency and acute onset interval during the follow-up period were observed and compared.Result：After treatment for 1 year,the FEV1,FEV1/FVC, FEV1% predicted values of the two groups after treatment were significantly higher than before treatment,and the above indexes of the treatment group were significantly higher than the control group,the differences were statistically significant（P〈0.05）.During the follow-up period,the acute onset frequency of the treatment group was significantly lower than the control group,the acute onset interval was significantly longer than the control group, the differences were statistically significant（P〈0.05）.Conclusion：The clinical efficacy of Macrolide Antibiotics combined with Salmeterol Assigned Powder Inhaler in the treatment of asthma COPD overlap syndrome is remarkable,can improve clinical symptoms and pulmonary function,reduce the frequency of attacks and extend the acute onset interval,is worthy of clinical use.